Susquehanna Fundamental Investments, LLC Akero Therapeutics, Inc. Transaction History
Susquehanna Fundamental Investments, LLC
- $6.94 Billion
- Q1 2025
A detailed history of Susquehanna Fundamental Investments, LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna Fundamental Investments, LLC holds 24,721 shares of AKRO stock, worth $945,578. This represents 0.01% of its overall portfolio holdings.
Number of Shares
24,721
Previous 8,390
194.65%
Holding current value
$945,578
Previous $233,000
329.18%
% of portfolio
0.01%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding AKRO
# of Institutions
270Shares Held
86MCall Options Held
1.02MPut Options Held
823K-
Rtw Investments, LP New York, NY7.42MShares$284 Million4.92% of portfolio
-
Janus Henderson Group PLC London, X07.07MShares$270 Million0.16% of portfolio
-
Wellington Management Group LLP Boston, MA5.94MShares$227 Million0.05% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$214 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$200 Million7.15% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $1.78B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...